Board of Directors

Jerome B. Zeldis, M.D., Ph.D.

Chairman of the Board

Dr. Zeldis is the Chief Medical Officer of Celgene Corporation and Chief Executive Officer of Celgene Global Health. Prior to joining Celgene in 1997, Dr. Zeldis held positions at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He currently serves as Chairman of the board of Alliqua and Trek Therapeutics in addition to board positions at Bionor Pharma, PTC Therapeutics, and Soligenix. He was Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School, and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. Dr. Zeldis received BA and MS degrees from Brown University, and M Phil, MD, and PhD degrees from Yale University. Dr. Zeldis has published 121 peer-reviewed articles and 24 reviews, as well as a number of book chapters, and editorials.

Douglas A. Hamilton, B.Sc., MBA

President and Chief Executive Officer

Mr. Hamilton was appointed President and Chief Executive Officer of the company on June 17, 2015 and has consulted for the company as acting Chief Financial Officer since August 2014. Mr. Hamilton has over 20 years experience in the life-sciences industry with broad domain expertise including financial management, management consulting, venture capital, and R&D operations management. Previously he served as CFO for SEA Medical Systems, a Silicon Valley health-tech company. In 2007, Mr. Hamilton founded and serves as Partner at New Biology Ventures, a life-sciences incubator accelerator and consulting firm. From 1999 to 2006, Mr. Hamilton served as CFO and COO for Javelin Pharmaceuticals, a commercial stage pharmaceutical company focused on the development and commercialization of a portfolio of acute pain medications. While at Javelin, Mr. Hamilton helped build a late stage product pipeline, took the company public, and raised over $82 million in financing. Prior to Javelin, Mr. Hamilton was the CFO and Director of Business Development for PolaRx Biopharmaceuticals, Inc. At PolaRx he helped developed the orphan drug Trisenox® and co-led the $45.2 million merger with Cell Therapeutics (currently owned by Teva Pharmaceuticals). Mr. Hamilton served as Project Manager for the Vfend® and Zithromax® product teams at Pfizer, in addition to the Aranesp®, Epogen®, Stemgen®, MGDF, and Cell Therapy product development teams at Amgen. Prior to Amgen, Mr. Hamilton served in the sales and marketing group at Pharmacia Biotech (now GE Healthcare Life Sciences), and in the recombinant DNA vaccine research group at Connaught Laboratories (now Sanofi-Pasteur). Mr. Hamilton earned his honors Bachelor of Science degree from the Department of Medical Genetics at the University of Toronto and his MBA from the Ivey Business School at Western University.